Active Filters

Stratification factors can reduce statistical power
Nov 3, 2022
Adding stratification factors can reduce a small trial’s statistical power
S1801 Melanoma Results at ESMO 2022
Sep 11, 2022
SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
S0931 EVEREST results at ASCO 2022
Jun 3, 2022
S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance
Lung-MAP S1800A results at ASCO 2022
Jun 3, 2022
Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.
ACA Medicaid Expansion and SWOG Trial Participants
Jun 1, 2022
Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid.
Standing CSF orders had limited impact
May 26, 2022
Adding standing physician orders to electronic record systems did not improve adherence to guidelines for prophylactic prescribing of colony-stimulating factors for febrile neutropenia for patients on high-risk or low-risk chemotherapy.
Desmoplastic melanoma responds to PD-1 blockade
May 26, 2022
A high rate of response to neoadjuvant PD-1 blockade in patients with desmoplastic melanoma suggests such therapy could reduce the extent of surgery needed on the face and neck.